Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer

NCT01589861 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

24

Enrollment

OTHER

Sponsor class

Stopped Drug development withdrawn

Conditions

Breast Cancer

Interventions

DRUG: BKM120 + lapatinib

Sponsor

Institut Paoli-Calmettes